Amniotic Products Market by Type, Application, End-User

List of Tables

[191 Pages Report] The Amniotic Products Market size was estimated at USD 1.06 billion in 2023 and expected to reach USD 1.16 billion in 2024, at a CAGR 10.12% to reach USD 2.08 billion by 2030.

Amniotic products are a category of regenerative medical therapies derived from amniotic tissues sourced from the placenta and amniotic membranes of human donors following a healthy, full-term pregnancy. These products are potentially used in various medical applications such as tissue regeneration, wound healing, pain management, inflammation control, orthopedics, ophthalmology, gynecology, and obstetrics. The expanding applications of amniotic-derived products in various medical fields and an increasing demand for these unique biological materials in regenerative medicine are increasing the need for amniotic products. However, the high cost associated with production, the need for specialized facilities, and stringent quality control measures are restricting the amniotic products market growth. Moreover, technological advancements such as decellularization techniques and the approval of regulatory bodies for clinical trials are expected to create opportunities for amniotic products.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.06 billion
Estimated Year [2024]	USD 1.16 billion
Forecast Year [2030]	USD 2.08 billion
CAGR (%)	10.12%

Type: Wide applications of amniotic membranes due to its exceptional healing potential

Amniotic membranes are present in the innermost layer of the placenta, comprising a thin, avascular tissue with unique healing properties. In cryopreserved Amniotic Membranes (CAMs), these membranes are biological scaffolds demonstrating exceptional healing potential. Dehydrated Amniotic Membranes (DAMs) are a vital component of amniotic products, which leverage the unique properties of human amniotic tissues to promote healing and regeneration. On the other hand, amniotic suspensions are preferred due to their potential effectiveness as injectable therapeutics and ease of use compared to complete membranes.

Application: Extensive use of amniotic products in ophthalmology to treat acute wounds

Amniotic products are used in orthopedics due to their ability to modulate inflammation, reduce pain, and facilitate tissue repair. Amniotic membrane allografts or injectable amniotic fluid-based products are commonly used in these cases. On the other hand, Wound care is another vital application segment for amniotic products due to their ability to promote rapid wound closure while minimizing scarring, making them ideal for treating acute wounds such as burns, surgical incisions, and diabetic foot ulcers. Amniotic products are used in ophthalmology to treat ocular surface disorders due to their anti-inflammatory, anti-scarring, and wound-healing properties. Conditions such as corneal ulcers, persistent epithelial defects (PEDs), dry eye syndrome (DES), and chemical burns can benefit from using amniotic membrane grafts.

End-User: Increasing use of amniotic products in hospitals for enhanced tissue regeneration and faster recovery

Ambulatory surgery centers (ASCs) are increasingly adopted for amniotic products due to their unique properties, such as faster healing time, reduced inflammation, and lower risk of infection. Amniotic products manage complex wounds effectively, reducing postoperative complications and facilitating quicker patient recovery. On the other hand, amniotic products in hospitals are used as demand for innovative treatment solutions to address complex medical cases requiring enhanced tissue regeneration and faster recovery periods.

Regional Insights

The increasing investment in research and a growing demand for regenerative medicine solutions have expanded the usage of amniotic products in the Americas. Investment from the public and private sectors is helping drive innovation in this market segment. In APAC countries such as China, Japan, and India, there is strong consumer interest in regenerative medicine therapies using amniotic products. In particular, advanced wound care management solutions are gaining traction due to rising cases of diabetes-related complications within their populations. Furthermore, government initiatives supporting research collaboration between public institutions and private enterprises have resulted in new technological advancements that utilize amniotic products. The European Union's Horizon 2020 program supports innovative projects in regenerative medicine, including those using amniotic products. Meanwhile, countries including Saudi Arabia and South Africa represent increasing demand for advanced wound care solutions that incorporate amniotic products. Recent regulatory changes favoring the use of human tissue-based products have also contributed to the growth within this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Amniotic Products Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Amniotic Products Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Amniotic Products Market, highlighting leading vendors and their innovative profiles. These include Akorn Operating Company LLC, Applied Biologics LLC, Celularity Inc., Corza Medical, Dallas Regenerative Solutions, Genesis Biologics Inc., Human Regenerative Technologies, LLC, Integra LifeSciences Holdings Corporation, LifeCell International Pvt. Ltd., Merakris Therapeutics Inc., MIMEDX Group, Inc., Next Biosciences Pty Limited, NuVision Biotherapies Ltd., Organogenesis Inc., Orthofix Medical Inc., Skye Biologics Holdings LLC, Smith & Nephew plc, STEMBIOSYS, INC, Stryker Corporation, Surgenex LLC, The Electrospinning Company, Tides Medical, TissueTech, Inc., Ventris Medical LLC, and VIVEX Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Amniotic Products Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Amniotic Membranes
  - Cryopreserved Amniotic Membranes
  - Dehydrated Amniotic Membranes

Amniotic Suspensions

Application
- Ophthalmology
- Orthopedics
- Wound Care

End-User
- Ambulatory Surgery Centers
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Amniotic Products Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Amniotic Products Market?

3. What are the technology trends and regulatory frameworks in the Amniotic Products Market?

4. What is the market share of the leading vendors in the Amniotic Products Market?

5. Which modes and strategic moves are suitable for entering the Amniotic Products Market?

Product Code: MRR-732E7CFCB109

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Potential demand attributed to chronic pains coupled with burn injuries
  - 5.1.1.2. Increasing number of ophthalmology and orthopedic surgeries worldwide
- 5.1.2. Restraints
  - 5.1.2.1. Concerns regarding limited availability of amniotic fluids
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous development of novel amniotic products
  - 5.1.3.2. Growing research activities in tissue engineering
- 5.1.4. Challenges
  - 5.1.4.1. Stringent amniotic product approval processes
5.2. Market Segmentation Analysis
- 5.2.1. Type: Wide applications of amniotic membranes due to its exceptional healing potential
- 5.2.2. Application: Extensive use of amniotic products in ophthalmology to treat acute wounds
- 5.2.3. End-User: Increasing use of amniotic products in hospitals for enhanced tissue regeneration and faster recovery
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Amniotic Products Market, by Type

6.1. Introduction
6.2. Amniotic Membranes
6.3. Amniotic Suspensions

7. Amniotic Products Market, by Application

7.1. Introduction
7.2. Ophthalmology
7.3. Orthopedics
7.4. Wound Care

8. Amniotic Products Market, by End-User

8.1. Introduction
8.2. Ambulatory Surgery Centers
8.3. Hospitals

9. Americas Amniotic Products Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Amniotic Products Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Amniotic Products Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft
- 12.3.2. MIMEDX Announces Commercial Launch of EPIFIX in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
- 12.3.3. Versea Launching Several Products in Ophthalmic Space
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio